The mission of the Penn ADCC is to increase research and education on AD, related dementias, normal brain aging and mild cognitive impairment (MCI), as well as support development of better diagnostics and preventions/treatments for AD and related disorders. The Penn ADCC provides research training, stimulates new research on normal aging and neurodegenerative dementias as well as development of novel techniques to address the challenges of conducting research on these disorders. The Penn ADCC is a highly interdisciplinary and seamlessly integrated Center with 5 Cores that collaborate extensively with other investigators at and beyond Penn, including the NIH/NIA funded AD Centers (ADCs), NACC, AD Cooperative Study (ADCS), AD Education and Referral (ADEAR) Center, the AD Neuroimaging Initiative (ADNI), AD Genetics Consortium (ADGC) and other NIH/public/private initiatives on AD, related disorders and healthy brain aging.
The Aims of the Penn ADCC are implemented through: 1) Administrative Core A to oversee and direct the activities of the ADCC;2) Clinical Core B to recruit, follow and study subjects with AD, MCI or related disorders and controls;3) Data Management and Biostatistics Core C to provide data management and biostatistical expertise;4) Neuropathology, Genetics and Biomarker Core D to establish postmortem diagnoses on ADCC subjects, and bank CNS tissues, DNA and biofluids from ADCC subjects for diagnostic studies and research;5) Education, Recruitment and Retention Core E to develop, implement and monitor recruitment and retention programs and ensure that the ADCC team as well as patients and families have up to- date knowledge of AD and related diseases;6) Pilot Grant Program to stimulate novel research on AD and related disorders;7) Collaborations with other investigators at and beyond Penn to improve diagnostics and treatments for AD and related disorders as well as increase understanding of these conditions and promote healthy brain aging. In summary, the Penn ADCC contributes to US and global strategies to meet the worldwide challenges of rapidly aging populations and the epidemic of AD and related disorders. In alignment with NIA RFA-AG-11- 005, the Penn ADCC accomplishes its mission in the renewal period through research on AD and related disorders as well as normal aging and through education to increase understanding of these disorders and their global effects.

Public Health Relevance

of the Penn ADCC is that it challenges/re-defines current clinical practice paradigms and research on AD and related disorders as well as MCI and normal aging by utilizing novel concepts and approaches to achieve the goals of this ADCC which are to increase research and education on AD, related dementias, normal brain aging and MCI, as well as support development of better diagnostics and preventions/treatments for AD and related disorders.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (M2))
Program Officer
Silverberg, Nina B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Schools of Medicine
United States
Zip Code
Hansson, Oskar; Seibyl, John; Stomrud, Erik et al. (2018) CSF biomarkers of Alzheimer's disease concord with amyloid-? PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement 14:1470-1481
Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161
Stites, Shana D; Harkins, Kristin; Rubright, Jonathan D et al. (2018) Relationships Between Cognitive Complaints and Quality of Life in Older Adults With Mild Cognitive Impairment, Mild Alzheimer Disease Dementia, and Normal Cognition. Alzheimer Dis Assoc Disord 32:276-283
Lleó, Alberto; Irwin, David J; Illán-Gala, Ignacio et al. (2018) A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. JAMA Neurol 75:738-745
Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487
Barupal, Dinesh Kumar; Fan, Sili; Wancewicz, Benjamin et al. (2018) Generation and quality control of lipidomics data for the alzheimer's disease neuroimaging initiative cohort. Sci Data 5:180263
He, Zhuohao; Guo, Jing L; McBride, Jennifer D et al. (2018) Amyloid-? plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med 24:29-38
Xie, Long; Das, Sandhitsu R; Wisse, Laura E M et al. (2018) Early Tau Burden Correlates with Higher Rate of Atrophy in Transentorhinal Cortex. J Alzheimers Dis 62:85-92
Martini-Stoica, Heidi; Cole, Allysa L; Swartzlander, Daniel B et al. (2018) TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. J Exp Med 215:2355-2377
Tropea, Thomas F; Xie, Sharon X; Rick, Jacqueline et al. (2018) APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson's disease. Mov Disord 33:289-297

Showing the most recent 10 out of 720 publications